Altimmune (ALT) Payables (2010 - 2026)

Altimmune (ALT) has 17 years of Payables data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Payables rose 42.06% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 42.06% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 1187.68% from the prior year.
• Payables for Q1 2026 stood at $1.5 million, down from $2.7 million in the prior quarter.
• Over the last five years, Payables for ALT reached as high as $5.2 million in Q1 2023 and fell as low as $211000.0 in Q4 2024.
• Historically, Payables has averaged $2.6 million across 5 years, with a median of $2.7 million in 2024.
• Across the five-year window, Payables jumped 23227.31% in 2022 and plunged 89.81% in 2024, its largest moves.
• Year by year, Payables stood at $4.8 million in 2022, then tumbled by 56.91% to $2.1 million in 2023, then plunged by 89.81% to $211000.0 in 2024, then jumped by 1187.68% to $2.7 million in 2025, then plunged by 43.69% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.5 million in Q1 2026, $2.7 million in Q4 2025, and $4.8 million in Q3 2025.